Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing

Autor: Valentina Ferrari, Alison Tarke, Hannah Fields, Tiffany N. Tanaka, Stephen Searles, Maurizio Zanetti

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

The PD-1:PD-L1 axis is a binary interaction that delivers inhibitory signals to T cells, impeding both immune surveillance and response to immunotherapy. Here we analyzed a phenomenon whereby tumor-specific T cells induce PD-L1 upregulation in autolo

Externí odkaz: https://doaj.org/article/e332476630c5488a88d3d7e592e6ceb5

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Autor: David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence J. Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany N. Tanaka, Joshua F. Zeidner, Guillermo Garcia-Manero, Deepa Jeyakumar, Rami Komrokji, Jeffrey Lancet, Hagop M. Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark Chao, Carol O'Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval G. Daver

Publikováno v: Journal of Clinical Oncology. 41:2815-2826

PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12e11b215e9336a1c069e5809c1a46c9
https://doi.org/10.1200/jco.22.01794

Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome

Autor: Colin McCarthy, Luca Ferrari, Hannah Fields, A Vitiello, Amber P. Sanchez, Franco Ferrari, Alison Tarke, Rafael Bejar, Tiffany N. Tanaka, Thomas A. Lane, Valentina Ferrari

Publikováno v: Cytotherapy. 23:236-241

Background Myelodysplastic syndromes (MDS) represent the most common type of acquired bone marrow failure in adults and is characterized by ineffective maturation of myeloid precursor cells and peripheral cytopenias associated with higher rates of in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28336fdce5345e365dde2e89a10fc68
https://doi.org/10.1016/j.jcyt.2020.11.003

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Autor: Giannis Mountzios, Massimo Martino, Alejandro Lazo-Langner, Namrata Peswani, Tiffany N. Tanaka, Kari Bohlke, Maryam B. Lustberg, Roberto Castelli, Gianluca Trifirò, Hushan Yang, Benjamin Djulbegovic, Julia Bohlius, Laura Porter

Publikováno v: Bohlius, Julia; Bohlke, Kari; Castelli, Roberto; Djulbegovic, Benjamin; Lustberg, Maryam B; Martino, Massimo; Mountzios, Giannis; Peswani, Namrata; Porter, Laura; Tanaka, Tiffany N; Trifirò, Gianluca; Yang, Hushan; Lazo-Langner, Alejandro (2019). Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood advances, 3(8), pp. 1197-1210. American Society of Hematology 10.1182/bloodadvances.2018030387
Bohlius, Julia; Bohlke, Kari; Castelli, Roberto; Djulbegovic, Benjamin; Lustberg, Maryam B; Martino, Massimo; Mountzios, Giannis; Peswani, Namrata; Porter, Laura; Tanaka, Tiffany N; Trifirò, Gianluca; Yang, Hushan; Lazo-Langner, Alejandro (2019). Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of clinical oncology, 37(15), pp. 1336-1351. American Society of Clinical Oncology 10.1200/JCO.18.02142

Purpose: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. Methods: PubMed and the Cochrane Library were search

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69df840be86c23db849ea55ee9c16ccb
https://doi.org/10.1200/jco.18.02142

DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages

Autor: Isidoro Cobo, Tiffany N. Tanaka, Kailash Chandra Mangalhara, Addison Lana, Calvin Yeang, Claudia Han, Johannes Schlachetzki, Jean Challcombe, Bethany R. Fixsen, Mashito Sakai, Rick Z. Li, Hannah Fields, Michal Mokry, Randy G. Tsai, Rafael Bejar, Koen Prange, Menno de Winther, Gerald S. Shadel, Christopher K. Glass

Publikováno v: Immunity, 55(8), 1386-1401.e10. Cell Press

Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated rol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66f8e053f041aefd7ae7ef22cd72a238
https://doi.org/10.1016/j.immuni.2022.06.022